Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Kimryn Rathmell

GU Oncology · Arthur G James Cancer Hospital

View

Dr. Patrick Pilie

GU Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Miksad

GI Oncology · BMC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MTDr. Mary-Ellen Taplin

    Dr. Mary-Ellen Taplin

    Medical Oncology · Genitourinary Oncology
    Dana-Farber Cancer Institute
    maryellen

    Research

    Impact of Pre-treatment Testosterone Levels on Severity of Adverse Effects in Men on Androgen Deprivation Therapy for Prostate Cancer

    2026

    Via Andrology

    Research

    Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial

    2026

    Via Clinical Cancer Research

    Research

    FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide

    2026

    Via European Urology

    Research

    Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1

    2026

    Via Journal of Clinical Oncology

    Research

    Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer

    2026

    Via Clinical Cancer Research

    Research

    HSD3B1 links ileal steroid metabolism to bile acid regulation in patients with prostate cancer

    2026

    Via The Journal of Clinical Investigation

    Aug 6, 2026Original Article

    Perioperative Apalutamide in High-Risk Localized Prostate Cancer

    ​

    Written by 1 Roon author & 22 others

    Via The New England Journal of Medicine

    Research

    Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4

    2026

    Via Journal of Clinical Oncology

    Research

    Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer

    2025

    Via ESMO Open

    Research

    Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer

    2025

    Via European Urology

    Research

    Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience

    2025

    Via The Prostate

    Research

    Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update

    2025

    Via Journal of Clinical Oncology

    Research

    Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review

    2025

    Via medRxiv (preprint)

    Research

    Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant

    2025

    Via The Prostate

    Research

    BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways

    2025

    Via Cell Reports